Simultaneous copy number gains of NUPR1 and ERBB2 predicting poor prognosis in early-stage breast cancer

BMC Cancer

Table 4 Results of multivariate aalysis

Variable	Hazard ratio	95% confidence interval		Pvalue*
		Lower	Upper
Using each RAR
Age	1.01	0.41	2.48	0.986
Stage	3.54	1.01	12.39	0.048
ER	1.63	0.61	4.34	0.325
PR	0.82	0.32	2.13	0.690
HER2	0.48	0.19	1.17	0.105
RAR-G12	2.55	0.73	8.90	0.141
RAR-G13	5.36	1.80	15.98	0.003
Using RAR double-positives
Age	1.00	0.41	2.44	0.993
Stage	3.73	1.06	13.04	0.040
ER	1.60	0.61	4.24	0.343
PR	0.84	0.32	2.15	0.709
HER2	0.46	0.19	1.14	0.094
RAR-G12*RAR-G13	7.31	2.65	20.15	0.0001

RAR-G12*RAR-G13: NUPR1 (RAR-G12) and ERBB2 (RAR-G13) copy number gain double-positives.
*Significant result (P < 0.05).

ISSN: 1471-2407